PURPOSE: To assess the feasibility of identifying patients with (atypical) MUTYH-associated polyposis (MAP) by KRAS2 c.34G > T prescreening followed by MUTYH hotspot mutation analysis in formalin-fixed paraffin-embedded tissue (FFPE). METHODS: We collected 210 colorectal FFPE tumors from 192 individuals who presented with <10 adenomas or familial mismatch repair proficient colorectal carcinomas with <10 concomitant adenomas. The tissues were tested for somatic KRAS2 mutations and for three Dutch hotspot MUTYH germ line mutations (p.Tyr165Cys, p.Gly382Asp, and p.Pro391Leu) by sequencing analysis. RESULTS: The c.34G > T, KRAS2 transversion was detected in 10 of 210 tumors. In one of these 10 cases, a monoallelic p.Gly382Asp MUTYH mutation was found and a full MUTYH analysis in leukocyte DNA revealed an unclassified variant p.Met269Val. This was in a 61-year-old patient with a cecum carcinoma and three adenomas. After further requests, her family case history revealed that her brother had had between 10 and 15 adenomas and turned out to carry both MUTYH germ line mutations. MUTYH hotspot mutation screening in 182 patients without the somatic c.34G > T KRAS2 mutation led to the detection of three monoallelic germ line MUTYH mutation carriers. CONCLUSION: KRAS2 c.34G > T somatic prescreening, followed by MUTYH hotspot mutation analysis when positive, can identify patients with (atypical) MAP. If heterozygous hotspot MUTYH mutations are identified, a complete germ line MUTYH mutation screening should be carried out if possible. Immediate MUTYH hotspot mutation analysis is a practical alternative in patients with >10 adenomas or in cases of multiple colorectal carcinomas in one generation for which only FFPE tissue is available.
PURPOSE: To assess the feasibility of identifying patients with (atypical) MUTYH-associated polyposis (MAP) by KRAS2 c.34G > T prescreening followed by MUTYH hotspot mutation analysis in formalin-fixed paraffin-embedded tissue (FFPE). METHODS: We collected 210 colorectal FFPE tumors from 192 individuals who presented with <10 adenomas or familial mismatch repair proficient colorectal carcinomas with <10 concomitant adenomas. The tissues were tested for somatic KRAS2 mutations and for three Dutch hotspot MUTYH germ line mutations (p.Tyr165Cys, p.Gly382Asp, and p.Pro391Leu) by sequencing analysis. RESULTS: The c.34G > T, KRAS2 transversion was detected in 10 of 210 tumors. In one of these 10 cases, a monoallelic p.Gly382AspMUTYH mutation was found and a full MUTYH analysis in leukocyte DNA revealed an unclassified variant p.Met269Val. This was in a 61-year-old patient with a cecum carcinoma and three adenomas. After further requests, her family case history revealed that her brother had had between 10 and 15 adenomas and turned out to carry both MUTYH germ line mutations. MUTYH hotspot mutation screening in 182 patients without the somatic c.34G > T KRAS2 mutation led to the detection of three monoallelic germ line MUTYH mutation carriers. CONCLUSION:KRAS2 c.34G > T somatic prescreening, followed by MUTYH hotspot mutation analysis when positive, can identify patients with (atypical) MAP. If heterozygous hotspot MUTYH mutations are identified, a complete germ line MUTYH mutation screening should be carried out if possible. Immediate MUTYH hotspot mutation analysis is a practical alternative in patients with >10 adenomas or in cases of multiple colorectal carcinomas in one generation for which only FFPE tissue is available.
Authors: María Dolores Giráldez; Francesc Balaguer; Luis Bujanda; Miriam Cuatrecasas; Jenifer Muñoz; Virginia Alonso-Espinaco; Mikel Larzabal; Anna Petit; Victoria Gonzalo; Teresa Ocaña; Leticia Moreira; José María Enríquez-Navascués; C Richard Boland; Ajay Goel; Antoni Castells; Sergi Castellví-Bel Journal: Clin Cancer Res Date: 2010-10-05 Impact factor: 12.531
Authors: Rachel S van der Post; Carolien M Kets; Marjolijn J L Ligtenberg; Joannes H J M van Krieken; Nicoline Hoogerbrugge Journal: Virchows Arch Date: 2008-11-25 Impact factor: 4.064
Authors: Ronald van Eijk; Marjo van Puijenbroek; Amiet R Chhatta; Nisha Gupta; Rolf H A M Vossen; Esther H Lips; Anne-Marie Cleton-Jansen; Hans Morreau; Tom van Wezel Journal: J Mol Diagn Date: 2009-12-03 Impact factor: 5.568
Authors: Eddy H J van Roon; Marjo van Puijenbroek; Anneke Middeldorp; Ronald van Eijk; Emile J de Meijer; Dianhdra Erasmus; Kim A D Wouters; Manon van Engeland; Jan Oosting; Frederik J Hes; Carli M J Tops; Tom van Wezel; Judith M Boer; Hans Morreau Journal: BMC Cancer Date: 2010-05-05 Impact factor: 4.430
Authors: Maartje Nielsen; Liza N van Steenbergen; Natalie Jones; Stefanie Vogt; Hans F A Vasen; Hans Morreau; Stefan Aretz; Julian R Sampson; Olaf M Dekkers; Maryska L G Janssen-Heijnen; Frederik J Hes Journal: J Natl Cancer Inst Date: 2010-11-02 Impact factor: 13.506
Authors: A P Knopperts; M Nielsen; R C Niessen; C M J Tops; B Jorritsma; J Varkevisser; J Wijnen; C L E Siezen; R C Heine-Bröring; H J van Kranen; Y J Vos; H Westers; E Kampman; R H Sijmons; F J Hes Journal: Fam Cancer Date: 2013-03 Impact factor: 2.375
Authors: Maartje Nielsen; Noel F C C de Miranda; Marjo van Puijenbroek; Ekaterina S Jordanova; Anneke Middeldorp; Tom van Wezel; Ronald van Eijk; Carli M J Tops; Hans F A Vasen; Frederik J Hes; Hans Morreau Journal: BMC Cancer Date: 2009-06-15 Impact factor: 4.430